Introduction {#section1-1849454417751735}
============

Dilated cardiomyopathy (DCM) is characterized by absence of secondary causes. Etiologies include hypertension, valvular dysfunction, coronary artery disease, myocarditis, and congenital pathophysiology. Approximately 50% of DCM patients carry an idiopathic etiology. In the absence of familial causes, idiopathic DCM (IDCM) is indistinguishable from the familial type.^[@bibr1-1849454417751735],[@bibr2-1849454417751735]^

Growth and differentiation factor-15 (GDF-15) is a cytokine of the Transforming Growth Factor (TGF)- beta superfamily first cloned and sequenced in 1997 from an activated macrophage cell system.^[@bibr3-1849454417751735]^ GDF-15 has been implicated in fibrosis, inflammation, and ventricular remodeling.^[@bibr4-1849454417751735][@bibr5-1849454417751735]--[@bibr6-1849454417751735]^ Soluble suppression of tumorigenicity-2 protein (sST2) is the circulating counterpart of the cellular receptor Suppression of Tumorigenity Ligand (ST2L). It is usually produced by cardiomyocytes and endothelial cells along with its ligand interleukin-33 (IL-33) during cardiomyocyte injury. IL-33 binds to ST2L and promotes inhibition of myocardial hypertrophy, fibrosis, and remodeling under normal conditions. On the other hand in pathological conditions such as heart failure, there is a large increase in the circulating form (sST2) which competes with the cellular form ST2L for the same ligand IL-33. This leads to pathogenesis as the protective role of ST2L is disrupted as sST2 binding to IL-33 does not result in inhibition of myocyte hypertrophy and remodeling. sST2 has therefore been postulated in prognosis and risk stratification of chronic heart failure.^[@bibr7-1849454417751735][@bibr8-1849454417751735]--[@bibr9-1849454417751735]^ Disruptions in the myocardial extracellular matrix (ECM) is the hallmark of structural pathology seen in heart failure; ECM is a dynamic unit. The synthesis and breakdown of ECM occurs via the actions of matrix metalloproteinases (MMPs) and their inhibitors (TIMPs). It has been postulated that ECM plays an active role in myocardial remodeling and interstitial transport in addition to acting as a reservoir for growth factors and cytokines involved in remodeling making them important of therapeutic targets.^[@bibr10-1849454417751735][@bibr11-1849454417751735]--[@bibr12-1849454417751735]^

The role of GDF-15 in regulation of cardiac remodeling in IDCM still remains poorly defined. This study was therefore undertaken to assess association of GDF-15 with metalloproteinases and sST2 which are molecular targets of fibrosis. The utility of these biomarkers in clinical evaluation of heart failure in IDCM will be investigated in this study from their correlation with New York heart Association (NYHA) class.

Materials and methods {#section2-1849454417751735}
=====================

The study population consisted of 24 DCM patients and 8 control subjects. This is a cross-sectional single center observational study. All DCM patients had normal angiographic studies. Plasma levels of GDF-15, sST2, MMP2, MMP3, MMP9, and TIMP1 were measured by enzyme-linked immunosorbent assays (ELISA). Blood was collected from patients in EDTA tubes, and BNP was measured as per core laboratory protocol assay at Scott and White Memorial Hospital core laboratory. Blood samples (5 ml) were collected from patients in standard EthyleneDiamineTetraacetic Acid (EDTA) tubes and centrifuged and plasma obtained was aliquoted into 100-ml Eppendorf tubes (Fisher Scientific, Hampton, USA) frozen at −800°C. The commercial ELISA kits used for GDF-15, MMP3, and sST2 were obtained from Aviscera Biosciences Inc (Santa Clara, California, USA). MMP2, MMP9, and TIMP1 ELISA kits were purchased from Ray Biotech Inc( Norcross, Georgia, USA). All analytes were quantitated using commercially available ELISA kits. They were all based on Sandwich ELISA principle wherein primary antibodies against the analyte were coated on a 96-well plate. Analyte was captured from serum samples by these primary antibodies, unbound matrix was washed off, and the bound analyte quantitated using a tagged detection antibody. Calibration curves were generated using serially diluted, pre-weighed analyte. The protocol followed was that obtained with the kit for use.

Left ventricular ejection fraction (LVEF) and left ventricular internal dimension in diastole (LVIDd) were obtained by two-dimensional (2-D) echocardiography. All echocardiographic examinations were done in the S&W echo laboratory The interoperator variation for scanning and reading was estimated at around 5%. Correlation analysis was performed between sST2 and GDF-15, MMP2, MMP3, MMP9, TIMP1, NYHA class, LVEF, and LVIDd using Microsoft Excel as well as VassarStats online program. The study protocol was approved by S&W IRB. Spearman rank-order correlation analyses wereperformed between GDF-15 and each of the MMPs---MMP2, MMP3, MMP9, TIMP1, and sST2 as well as NYHA class and echocardiographic parameters (LVEF and LVIDd). LVEF and LVIDd were obtained by 2-D echocardiography. The protocol was approved by S&W IRB. All statistical analyses were performed using the VassarStats online program. Statistical significance was set at *p* \< 0.05. Tables show both the one-tailed and two-tailed *p* values. Individual patient values used for correlations and the corresponding scatter plots have been provided in the Online Supplementary Material.

Results {#section3-1849454417751735}
=======

Characteristics of study population {#section4-1849454417751735}
-----------------------------------

[Table 1](#table1-1849454417751735){ref-type="table"} summarizes the characteristics of the study population. BNP levels, LVIDd, and ejection fraction were significantly different from the DCM versus controlled subjects. Male comprised of 84% of the DCM group, while male and female were almost equally represented in the control group. This unequal gender representation in the two groups was not intentional. [Table 2](#table2-1849454417751735){ref-type="table"} shows that all the five biomarkers analyzed such as GDF-15, MMP2, MMP3, MMP9, and TIMP1 were significantly upregulated in the DCM subjects.

###### 

Characteristics of study population.

![](10.1177_1849454417751735-table1)

  Baseline characteristic   Control (*n* = 9)   DCM (*n* = 23)   *p* Value
  ------------------------- ------------------- ---------------- ------------
  Age (years)               58.3 ± 10.3         50.4 ± 34        0.18
  Gender                                                         
   Male                     56%                 84%              Nd
   Female                   44%                 16%              Nd
  BNP (pg/ml)               50 ± 38             1653 ± 45        0.0006\*
  LVIDd (cm)                4.5 ± 0.3           6.5 ± 0.5        \<0.0001\*
  LVEF (%)                  63.1 ± 7.4          21.6 ± 8.4       \<0.0001\*
  Creatinine (mg/dl)        0.87 ± 0.12         1.6 ± 2.1        0.28

DCM: dilated cardiomyopathy; LVIDd: left ventricular internal dimension in diastole; LVEF: left ventricular ejection fraction; Nd: Not done.

\**p* \< 0.05 was considered significant.

###### 

Biomarker levels in control and DCM populations.

![](10.1177_1849454417751735-table2)

  ** **                  GDF-15 (pg/ml)   MMP2 (ng/ml)   MMP9 (ng/ml)   TIMP1 (ng/ml)   MMP3 (ng/ml)
  ---------------------- ---------------- -------------- -------------- --------------- --------------
  Control (*n* = 8)      516 ± 146        626 ± 100      592 ± 210      280 ± 23        5.5 ± 2
  DCM (*n* = 24)         3203 ± 1354      848 ± 167      976 ± 238      565 ± 173       9.7 ± 2.8
  One-tailed *p*value    0.01             0.01           0.006          0.001           0.006
  Two-tailed *p* value   0.02             0.02           0.013          0.002           0.013

GDF: growth and differentiation factor-15; MMP: matrix metalloproteinase; TIMP1: tissue inhibitor of MMP 1; DCM: dilated cardiomyopathy; sST2: soluble suppression of tumorigenicity-2 protein.

Correlation of GDF-15 with MMPs {#section5-1849454417751735}
-------------------------------

Correlation of GDF-15 with MMPs is shown in [Table 3](#table3-1849454417751735){ref-type="table"}. Correlation analysis of control versus DCM patients showed a strong correlation of GDF-15 with TIMP1 (*r* = 0.83, *p* \< 0.0001) and weaker correlation with MMP3 (*r* = 0.41, *p* = 0.011) and MMP2 (*r* = 0.47, *p* = 0.003). Correlation with MMP9 was only borderline significant (*r* = 0.3036, *p* = 0.046). GDF-15 correlated negatively with MMP2/TIMP1 ratio (*r* = −0.24, *p* = 0.09) but was not statistically significant at *p* \< 0.05. [Figure 1(a) to (e)](#fig1-1849454417751735){ref-type="fig"} shows the scatter plots for the correlations between GDF-15 and TIMP1, MMP2, MMP3, MMP9, and MMP2/TIMP1 ratio, respectively.

###### 

Correlation of GDF-15 with MMPs.

![](10.1177_1849454417751735-table3)

               Correlation coefficient (*r~s~*)   *p* Value (one-tailed)   *p* Value (two-tailed)
  ------------ ---------------------------------- ------------------------ ------------------------
  TIMP1        0.83                               *p* \< 0.00001           *p* \< 0.00001
  MMP2         0.47                               *p* = 0.003              *p* = 0.006
  MMP3         0.41                               *p* = 0.011              *p* = 0.022
  MMP9         0.304                              *p* = 0.046              *p* = 0.092
  MMP2/TIMP1   −0.24                              *p* = 0.09               *p* = 0.19

GDF: growth and differentiation factor-15; MMP: matrix metalloproteinase; TIMP1: tissue inhibitor of MMP 1.

![The scatter plots depicting the correlations between GDF-15 and TIMP1, MMP2, MMP3, MMP9, and MMP2/TIMP1 ratio. GDF: growth and differentiation factor-15; MMP: matrix metalloproteinase; TIMP1: tissue inhibitor of MMP 1.](10.1177_1849454417751735-fig1){#fig1-1849454417751735}

Correlation of GDF-15 with worsening function and echocardiographic parameters {#section6-1849454417751735}
------------------------------------------------------------------------------

[Table 4](#table4-1849454417751735){ref-type="table"} shows GDF-15 correlated negatively with LVEF (*r* = −0.49, *p* = 0.003) and positively with LVIDd (*r* = 0.5, *p* = 0.002). GDF-15 showed significant positive correlation with NYHA functional class (*r* = 0.71, *p* \< 0.00001) and BNP (*r* = 0.51, *p* = 0.002). [Figure 2(a) to (d)](#fig2-1849454417751735){ref-type="fig"} shows the scatter plots for the correlations between GDF-15 and NYHA class, LVIDd, LVEF, and BNP, respectively.

###### 

Correlation of GDF-15 with NYHA class, LVIDd, LVEF, and BNP.

![](10.1177_1849454417751735-table4)

               Correlation coefficient (*r~s~*)   *p* Value (one-tailed)   *p* Value (two-tailed)
  ------------ ---------------------------------- ------------------------ ------------------------
  NYHA class   0.7                                *p* = 0.0001             *p* = 0.0002
  LVIDd        0.5                                *p* = 0.002              *p* = 0.004
  LVEF         −0.49                              *p* = 0.003              *p* = 0.007
  BNP          0.51                               *p* = 0.002              *p* = 0.004

GDF: growth and differentiation factor-15; NYHA: New York Heart Association; LVIDd: left ventricular internal dimension in diastole; LVEF: left ventricular ejection fraction.

![The scatter plots depicting the correlations between GDF-15 and NYHA class, LVIDd, LVEF, and BNP. GDF: growth and differentiation factor-15; NYHA: New York Heart Association; LVIDd: left ventricular internal dimension in diastole; LVEF: left ventricular ejection fraction.](10.1177_1849454417751735-fig2){#fig2-1849454417751735}

Correlation of sST2 with GDF-15, MMPs, worsening function, and echocardiographic parameters {#section7-1849454417751735}
-------------------------------------------------------------------------------------------

[Table 5](#table5-1849454417751735){ref-type="table"} shows correlation of sST2 with GDF-15 and MMPs. Plasma sST2 correlated strongly with GDF-15 (*r* = 0.7, *p* = 0.000005) and TIMP1 (*r* = 0.68, *p* = 0.00007). Moderate correlation was noted with MMP2 (*r* = 0.48, *p* = 0.003) and weaker correlation with MMP3 (*r* = 0.31, *p* = 0.04). MMP9 showed poor correlation with no essential statistical significance (*r* = 0.31, *p* = 0.06). [Figure 3(a) to (e)](#fig3-1849454417751735){ref-type="fig"} shows the scatter plots for the correlations between sST2 and GDF-15, TIMP1, MMP2, MMP3, and MMP9, respectively. Interestingly, sST2 correlated significantly with NYHA class (*r* = 0.31, *p* = 0.000012) but not with LVEF or LVIDd as shown in [Table 6](#table6-1849454417751735){ref-type="table"}. [Figure 4(a) to (c)](#fig4-1849454417751735){ref-type="fig"} shows the scatter plots for the correlations between sST2 and NYHA class, LVEF, and LVIDd, respectively.

###### 

Correlation of sST2 with GDF-15 and MMPs.

![](10.1177_1849454417751735-table5)

           Correlation coefficient (*r~s~*)   *p* Value (one-tailed)   *p* Value (two-tailed)
  -------- ---------------------------------- ------------------------ ------------------------
  GDF-15   0.7                                *p* = 0.000005           *p* = 0.00001
  TIMP1    0.63                               *p* = 0.00007            *p* = 0.00015
  MMP2     0.48                               *p* = 0.003              *p* = 0.006
  MMP3     0.31                               *p* = 0.04               *p* = 0.08
  MMP9     0.31                               *p* = 0.06               *p* = 0.12

GDF: growth and differentiation factor-15; MMP: matrix metalloproteinase; TIMP1: tissue inhibitor of MMP 1; sST2: soluble suppression of tumorigenicity-2 protein.

![The scatter plots depicting the correlations between sST2 and GDF-15, TIMP1, MMP2, MMP3, and MMP9. sST2: soluble suppression of tumorigenicity-2 protein; GDF: growth and differentiation factor-15; MMP: matrix metalloproteinase; TIMP1: tissue inhibitor of MMP 1.](10.1177_1849454417751735-fig3){#fig3-1849454417751735}

###### 

Correlation of sST2 with NYHA class, LVEF, and LVIDd.

![](10.1177_1849454417751735-table6)

               Correlation coefficient (*r~s~*)   *p* Value (one-tailed)   *p* Value (two-tailed)
  ------------ ---------------------------------- ------------------------ ------------------------
  NYHA class   0.67                               *p* = 0.000012           *p* = 0.000024
  LVEF         0.26                               *p* = 0.05               *p* = 0.1
  LVIDd        0.32                               *p* = 0.03               *p* = −0.07

sST2: soluble suppression of tumorigenicity-2 protein; NYHA: New York Heart Association; LVIDd: left ventricular internal dimension in diastole; LVEF: left ventricular ejection fraction.

![The scatter plots depicting the correlations between sST2 and NYHA class, LVEF, and LVIDd. sST2: soluble suppression of tumorigenicity-2 protein; NYHA: New York Heart Association; LVIDd: left ventricular internal dimension in diastole; LVEF: left ventricular ejection fraction.](10.1177_1849454417751735-fig4){#fig4-1849454417751735}

Discussion {#section8-1849454417751735}
==========

GDF-15 has been implicated in fibrosis, inflammation, and ventricular remodeling. The role of GDF-15 in regulation of cardiac remodeling in IDCM is not well-defined. This study has attempted to address the association of GDF-15 with sST2 and metalloproteinases, which are possible molecular targets of regulation in pathogenesis of DCM. Pathophysiology of IDCM at the molecular and cellular levels remains poorly understood. The correlations of sST2 with GDF-15 and MMPs show significant associations between these molecules.

In this study of IDCM patients, GDF-15 appears to have significant associations with markers of fibrosis and remodeling such as soluble ST2 and MMPs. Additionally, in our study, GDF-15 appears to significantly correlate with structural (echocardiographic) and functional (NYHA class) parameters of cardiac function. Increases in GDF-15 in heart failure and its negative correlations with LVEF as well as positive correlations with LVIDd suggest that GDF-15 possibly influences structure/functional interactions affecting ventricular remodeling in these patients and that such influences could influence mortality. However, most of the existing studies on GDF-15 upregulation are in heart failure patient populations with heterogeneous etiologies.^[@bibr13-1849454417751735],[@bibr14-1849454417751735]^

A strong correlation between improved ejection fraction and decreased mortality has been demonstrated in a recent meta-analysis.^[@bibr15-1849454417751735]^ In another study of an acute heart failure population of mixed etiologies, increases in GDF-15 were associated with a greater risk of 60-day heart failure rehospitalizations/cardiovascular death as well as cardiac death at 180 days.^[@bibr16-1849454417751735]^ In a meta-analysis of a heterogeneous heart failure population, elevated GDF-15 levels were associated with increased risk of mortality.^[@bibr17-1849454417751735]^ Further studies are needed for better characterization of GDF-15 use in prognostication in heart failure populations of specific etiologies.

This study focuses on a single group of well-characterized IDCM patients at a single center. Patients with DCM in this study had no coronary artery disease as evidenced by coronary angiography. We present here some findings for the first time in IDCM population which will possibly open up pathways of investigation to further knowledge on role of GDF-15 and markers of fibrosis such as soluble ST2 and the MMPs on ventricular remodeling in this population. GDF-15 correlates significantly and positively with NYHA class and worsening functionality. GDF-15 negatively correlates with MMP2/TIMP1. This finding sheds light on effect of GDF-15 on metalloproteinase metabolism, therefore suggesting a role in ventricular fibrosis and remodeling. It is also noteworthy that GDF-15 strongly correlates with BNP suggesting that GDF-15 is released analogous to the natriuretic peptides in response to cardiac injury signaling a possible protective response.

[Figure 5](#fig5-1849454417751735){ref-type="fig"} shows a possible effect of interactions of GDF-15, sST2, and MMPs on alterations in collagen I/III ratios, MMP/TIMP ratios, and increased myosin heavy chain degradation; all of which could contribute to loss of myocytes/ventricular fibrosis/remodeling.^[@bibr18-1849454417751735]^ GDF-15 has also been implicated in anti-apoptosis as well as induction of hypertrophy in ventricular myocytes^[@bibr19-1849454417751735]^ further contributing to ventricular remodeling.

![A summary of possible interactions of GDF-15 with soluble ST2 and MMPs in DCM. GDF: growth and differentiation factor-15; MMP: matrix metalloproteinase; DCM: dilated cardiomyopathy.](10.1177_1849454417751735-fig5){#fig5-1849454417751735}

A delicate balance between MMPs and TIMPs has always been postulated in preventing adverse remodeling, but circulating levels of TIMP1 have been shown in human DCM to be elevated.^[@bibr20-1849454417751735]^ The levels of circulating biomarkers appear to be different in their concentrations and trends as compared to all the literature on tissue samples where MMPs and TIMPs seem to hold an inverse relationship.^[@bibr20-1849454417751735],[@bibr21-1849454417751735]^ Many factors such as cytokines, hormones and growth factors and stage of DCM as well as extent of upregulation of the neurohormonal system may operate synergistically to regulate the levels of MMPs and TIMPs in the myocardial tissue versus in circulation. It is unclear if the extent of inflammation also influences the level balance between MMPs and TIMPs in the remodeling processes.^[@bibr20-1849454417751735],[@bibr21-1849454417751735]^ Hence, differences noted in this small study will need to be further investigated in different stages of DCM progression to determine whether changes in MMPS/TIMPs would change with disease severity.

BNP is known to counteract the hemodynamic stress by inducing vasodilation, natriuresis, and diuresis. The cardioprotective properties of ST2 and IL-33 are also well established. The protective effects in the heart of GDF-15 occur through inhibition of apoptosis, hypertrophy, and adverse remodeling in the injured heart. Correlations between GDF-15, BNP, and sST2 serve to address the complicated interactions that may exist in myocardial stress.^[@bibr22-1849454417751735][@bibr23-1849454417751735][@bibr24-1849454417751735]--[@bibr25-1849454417751735]^ It is however important to note that protective roles of these molecules may vary in efficiency as the disease progresses; hence, further studies are warranted in this domain.

Limitations {#section9-1849454417751735}
===========

The study is limited by its small population size and the fact that GDF-15 and all the biomarkers described here were only assayed in circulation. Site of production of GDF-15 in heart failure of different etiologies still remains ambiguous.^[@bibr25-1849454417751735],[@bibr26-1849454417751735]^

Conclusions {#section10-1849454417751735}
===========

This study shows for the first time that the strongest relationships were between GDF-15 and NYHA class as well as between GDF15 and TIMP, sST2 with GDF-15, and with TIMP in IDCM patients. This investigation opens the pathway for newer investigations on interactions between these molecular markers of fibrosis in the process of ventricular remodeling and dysfunction. Further studies are required to precisely define the molecular interactions between GDF-15, sST2, and MMPs in ventricular remodeling as well as influencing worsening functional capacity in DCM.

Future directions {#section11-1849454417751735}
=================

Precise studies to elucidate the extent of changes in MMPs, TIMPs, and biomarkers of heart failure such as GDF-15 and soluble standard deviation in relation to BNP need to be undertaken. This is especially needed in the context of disease progression in order to help with prognostication and development of therapeutics. Protective roles of BNP, GDF-15, and ST2 should be studied in the context of worsening heart failure and disease progression. Interactions between GDF-15, BNP, and soluble ST2 need to be further investigated in order to define molecular mechanisms that work in synergy when subjected to myocardial strain and remodeling. Another area of importance is to investigate the use of these biomarkers and heart failure to monitor therapy and progression of disease. Further studies would help in developing a panel of biomarkers which can be used to risk stratify as well as for the development of therapeutics as interactions between biomarkers define the convergence divergence of complex biochemical pathways. This is especially important as heart failure is a complex syndrome where interactions between inflammation, myocardial strain, and remodeling contribute to the pathophysiology and progression of the disease.
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